NCT01126047

Brief Summary

The purpose of this study is to check the accuracy of a procedure called exhaled carbon monoxide (eCO) testing. Exhaled carbon monoxide is used by physicians to help assess breathing in people with conditions like asthma and emphysema. eCO may be used to correct another breathing test (called diffusing capacity, or DLCO). Blood collection is usually required to correct the DLCO, so validation of the eCO test may help avoid that blood collection.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started May 2010

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2010

Completed
13 days until next milestone

First Submitted

Initial submission to the registry

May 14, 2010

Completed
5 days until next milestone

First Posted

Study publicly available on registry

May 19, 2010

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2011

Completed
Last Updated

November 9, 2011

Status Verified

November 1, 2011

Enrollment Period

1.5 years

First QC Date

May 14, 2010

Last Update Submit

November 7, 2011

Conditions

Keywords

Lung Diseases

Outcome Measures

Primary Outcomes (1)

  • Exhaled carbon monoxide as a predictor of carboxyhemoglobin

    Exhaled carbon monoxide will be evaluated as a predictor of carboxyhemoglobin and change in diffusing capacity with increasing carboxyhemoglobin

    1 year

Study Arms (1)

PFT's, eCO, and pulse oximetry

OTHER

All subjects in the study will undergo complete pulmonary function testing (spirometry, blood collection for carboxyhemoglobin, diffusing capacity); exhaled carbon-monoxide testing, and pulse oximetry.

Other: eCO testing

Interventions

exhaled carbon monoxide testing measured in duplicate on each of 2 machines immediately prior to the carboxyhemoglobin blood draw and four minutes after the clinical measurement of DLCO

PFT's, eCO, and pulse oximetry

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients who will at minimum have spirometry, diffusing capacity and CO-oximetry performed for any clinical indication (Part 1 only)
  • Willingness to under go the study procedures.
  • Ability to give written informed consent to participate in the study.

You may not qualify if:

  • Subjects on oxygen therapy within 1 hour. High levels of oxygen are used to displace CO in cases of toxicity. Presumably those recently on lower flows of oxygen are not in a steady state for several half-lives.
  • Self-reported smoking within 1-hour.
  • Significant exercise within 15 minutes
  • Recent (within 2 hrs) alcohol consumption (alcohol can interfere with the DLCO measurement)
  • Subjects unwilling to remove nail polish from one finger
  • Known atypical hemoglobin types (e.g. sickle cell trait or disease, thalassemia etc). The binding and release of oxygen and presumably CO is altered in these types of hemoglobinopathies
  • History of known or suspected alveolar hemorrhage. Free hemoglobin or red cells in the alveolus markedly raise the DLCO and theoretically might alter the eCO.
  • Known or suspected intestinal bacterial overgrowth. Although the cross reactivity of the CO sensor for hydrogen is \<2%, high values of hydrogen from bacterial overgrowth, may lead to erroneous CO measurements.
  • Tracheostomy or inability to form a tight seal around the mouthpiece.
  • Prior participation in the same part of this study (i.e., subjects can participate in Part 1 and Part 2, but not twice in Part 1, or twice in Part 2)
  • Inability to perform spirometry and diffusing capacity
  • Inability to consent
  • Other diseases or conditions that may, in the opinion of the investigator, result in invalid pulmonary function tests or eCO measurement.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

UCLA

Los Angeles, California, 90095, United States

Location

West LA VA

Los Angeles, California, 90095, United States

Location

MeSH Terms

Conditions

Lung Diseases

Condition Hierarchy (Ancestors)

Respiratory Tract Diseases

Study Officials

  • Michelle R Zeidler, MD

    UCLA, VA

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Professor

Study Record Dates

First Submitted

May 14, 2010

First Posted

May 19, 2010

Study Start

May 1, 2010

Primary Completion

November 1, 2011

Study Completion

November 1, 2011

Last Updated

November 9, 2011

Record last verified: 2011-11

Locations